胰腺癌患者冷冻消融治疗前后血清CD44v6和整合素β1的变化及在预后评估中的意义

doi:10.3969/j.issn.1673-8640.2013.12.005

检验医学 ›› 2013, Vol. 28 ›› Issue (12): 1083-1087.DOI: 10.3969/j.issn.1673-8640.2013.12.005

胰腺癌患者冷冻消融治疗前后血清CD44v6和整合素β1的变化及在预后评估中的意义

黄红莉¹，周刚¹，牛立志²，石红霞²，孔小峰²，王峰²，徐克成²

1.中国科学院广州生物医药与健康研究院附属复大医院PCR检测室，广东广州 510310；2.广州复大肿瘤医院肿瘤科，广东广州 510305

出版日期:2013-12-01 发布日期:2013-12-20
通讯作者: 徐克成，联系电话:020-8217418。
作者简介:黄红莉，女，1976年生，学士，主管技师，主要从事肿瘤标志物的检测研究。
基金资助:
广东省医学科学技术研究基金资助项目(WSTJJ20090401440106196602154756)

The changes of serum CD44v6 and integrin beta 1 before and after cryosurgery in patients with pancreatic cancer and the significance in prognosis evaluation

HUANG Hongli¹,ZHOU Gang¹,NIU Lizhi²,SHI Hongxia²,KONG Xiaofeng²,WANG Feng²,XU Kecheng².

1. Department of PCR Detection, Guangzhou Institutes of Biomedicine and Health Affiliated Fuda Hospital, Chinese Academy of Sciences, Guangdong Guangzhou 510310, China；2.Department of Oncology,Fuda Cancer Hospital, Guangdong Guangzhou 510305, China

Online:2013-12-01 Published:2013-12-20

摘要/Abstract

摘要：

目的　探讨胰腺癌患者冷冻消融治疗前后血清中CD44v6及整合素β1表达水平的变化及与预后的相关性。方法　44例胰腺癌患者行冷冻消融治疗术，收集患者治疗前后及20名正常人(对照组)的血清标本，采用酶联免疫吸附试验(ELISA)测定CD44v6及整合素β1在血清中的表达水平。结果　与对照组比较，患者术前和术后10dCD44v6和整合素β1的表达水平均较高(P<0.05)，而术后1个月的表达水平与对照组差异无统计学意义(P>0.05);术后患者的CD44v6和整合素β1的表达水平均逐渐下降，术后1个月二者的表达水平均明显低于术前(P<0.05)。CD44v6和整合素β1的表达水平与肿瘤大小、分化、临床分期、淋巴结转移及肝转移均明显相关(P<0.05)，而与患者性别、年龄及肿瘤位置均无相关性(P>0.05)。CD44v6和整合素β1低表达患者术后的中位生存期分别为14.5个月和14.2个月，而高表达患者仅为9.5个月和9.8个月，二者间差异均有统计学意义(P<0.05)。结论　CD44v6和整合素β1的血清表达水平与胰腺癌的发生、发展、转移及预后等密切相关。

关键词: CD44v6, 整合素β1, 胰腺癌, 预后, 冷冻消融治疗术

Abstract:

Objective　 To investigate the changes of the expression levels of serum CD44v6 and integrin beta 1 in patients with pancreatic cancer before and after cryosurgery and the correlation between the expression levels and prognosis. Methods　 Cryosurgery was conducted in 44 patients with pancreatic cancer. Serum samples were collected from the patients before and after cryosurgery and 20 healthy subjects (control group). Enzyme-linked immunosorbent assay (ELISA) was used to detect the expression levels of serum CD44v6 and integrin beta 1. Results　 Compared with the control group,the expression levels of CD44v6 and integrin beta 1 in patients before and after cryosurgery for 10 d were higher (P<0.05). No statistical significance was found between the patients after cryosurgery for 1 month and the control group (P>0.05). The CD44v6 and integrin beta 1 expression levels decreased gradually after cryosurgery. The expression levels of CD44v6 and integrin beta 1 in patients after cryosurgery for 1 month were significantly lower than those in patients before cryosurgery (P<0.05). Both CD44v6 and integrin beta 1 expression levels were significantly correlated with tumor size,tumor differentiation,clinical stage,lymph node metastasis and liver metastasis (P<0.05),while they were not correlated with sex, age and tumor location (P>0.05). The median survival times of patients with low CD44v6 and integrin beta 1 expressions were 14.5 months and 14.2 months,while those of patients with high CD44v6 and intergrin beta 1 expressions were only 9.5 months and 9.8 months. There were statistical significances (P<0.05). Conclusions　 Serum CD44v6 and integrin beta 1 expression levels are closely correlated to the development,invasion,metastasis and prognosis of pancreatic cancer.

Key words: CD44v6, Integrin beta 1, Pancreatic cancer, Prognosis, Cryosurgery

中图分类号:

R446.62

黄红莉，周刚，牛立志，石红霞，孔小峰，王峰，徐克成. 胰腺癌患者冷冻消融治疗前后血清CD44v6和整合素β1的变化及在预后评估中的意义[J]. 检验医学, 2013, 28(12): 1083-1087.

HUANG Hongli,ZHOU Gang,NIU Lizhi,SHI Hongxia,KONG Xiaofeng,WANG Feng,XU Kecheng.. The changes of serum CD44v6 and integrin beta 1 before and after cryosurgery in patients with pancreatic cancer and the significance in prognosis evaluation[J]. , 2013, 28(12): 1083-1087.

[1]	王杨淑怡, 叶威, 林志豪, 黄约诺, 方涛, 董晓亭. 肺腺癌焦亡相关特征模型的构建和验证[J]. 检验医学, 2023, 38(9): 833-841.
[2]	张寒, 李军, 刘小江, 管义祥. 白蛋白、白细胞介素6和铁蛋白联合检测在评估自发性脑出血患者功能预后中的价值[J]. 检验医学, 2023, 38(8): 713-718.
[3]	张娜, 牛伟华, 孙媛媛, 贾玫. CMV和EBV共感染可影响造血干细胞移植患者预后[J]. 检验医学, 2023, 38(8): 760-765.
[4]	郭洁, 李海霞, 李小云. 术前外周血红细胞分布宽度/血小板计数比值与子宫内膜癌患者预后的相关性[J]. 检验医学, 2023, 38(7): 675-679.
[5]	王腾飞, 陈珊, 安和兵, 周蕾. 急性白血病患者外周血lncRNA CRNDE、miR-384表达及其临床意义[J]. 检验医学, 2023, 38(7): 686-691.
[6]	张春玲, 蔺丽慧, 王小蕊, 丁静, 李莉. 成人KMT2A/MLLT6阳性急性髓系白血病1例报道并文献复习[J]. 检验医学, 2023, 38(7): 704-706.
[7]	尹娅, 潘沅, 周宏伟, 沈薇. BNP和NT-proBNP在新生儿心血管疾病中的应用进展[J]. 检验医学, 2023, 38(6): 518-523.
[8]	赵婧, 王佩, 卢丹丹, 齐丹丹, 李轩. 出血性脑卒中患者血清miR-4443、TRAF4相对表达量变化的临床意义[J]. 检验医学, 2023, 38(5): 413-418.
[9]	宋世伟, 李景武, 林韬, 刘泽宇, 王志强, 孙卫东. GPNMB与非小细胞肺癌患者肿瘤免疫浸润和预后的相关性[J]. 检验医学, 2023, 38(4): 347-351.
[10]	刘俊闪, 郭明发, 孙佳, 史利欢, 刘炜, 段勇涛. 微量残留病监测在ETV6/RUNX1阴性和阳性急性B淋巴细胞白血病患儿预后中的意义[J]. 检验医学, 2023, 38(3): 209-214.
[11]	陈哲, 张灵, 刘洁, 王霞, 张斌, 高炳华. 血清miR-326与治疗相关性血液系统恶性肿瘤患者化疗敏感性和预后的关系[J]. 检验医学, 2023, 38(3): 251-256.
[12]	李志霞, 肖华, 卓芬, 李存盈, 李绍武, 王玉丰. 外周血LYMPH#、MO#、LMR在DLBCL患者预后评估中的价值[J]. 检验医学, 2023, 38(12): 1198-1201.
[13]	顾怡, 王蕊, 邓杰, 杨易静, 周王柯, 陈予诺, 陈小松, 沈薇, 周景艺. 重症肝炎和肝硬化患者肝移植前后生物标志物水平差异及其预后评估价值[J]. 检验医学, 2023, 38(11): 1044-1051.
[14]	梁卫章, 石建平, 柴丽娜, 韩爱子. 血清组织蛋白酶K、解聚蛋白样金属蛋白酶-7与慢性心力衰竭患者心室重构和预后的关系[J]. 检验医学, 2023, 38(10): 919-925.
[15]	周军, 李立恒, 张敏. 口腔腺样囊性癌患者血清miR-24、XIAP mRNA表达及其与预后的相关性[J]. 检验医学, 2023, 38(10): 930-935.

胰腺癌患者冷冻消融治疗前后血清CD44v6和整合素β1的变化及在预后评估中的意义

The changes of serum CD44v6 and integrin beta 1 before and after cryosurgery in patients with pancreatic cancer and the significance in prognosis evaluation

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics